| Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease M Pons, S Augustin, B Scheiner, M Guillaume, M Rosselli, SG Rodrigues, ... Official journal of the American College of Gastroenterology| ACG 116 (4 …, 2021 | 137 | 2021 |
| Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon‐free therapy M Mandorfer, K Kozbial, P Schwabl, D Chromy, G Semmler, ... Hepatology 71 (3), 1023-1036, 2020 | 118 | 2020 |
| Diet and exercise in NAFLD/NASH: beyond the obvious G Semmler, C Datz, T Reiberger, M Trauner Liver International 41 (10), 2249-2268, 2021 | 86 | 2021 |
| HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease G Semmler, EL Meyer, K Kozbial, P Schwabl, S Hametner-Schreil, ... Journal of hepatology 76 (4), 812-821, 2022 | 70 | 2022 |
| Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease B Scheiner, G Semmler, F Maurer, P Schwabl, TA Bucsics, R Paternostro, ... Liver International 40 (1), 194-204, 2020 | 65 | 2020 |
| Does the functional liver imaging score derived from gadoxetic acid–enhanced MRI predict outcomes in chronic liver disease? N Bastati, L Beer, M Mandorfer, S Poetter-Lang, D Tamandl, Y Bican, ... Radiology 294 (1), 98-107, 2020 | 58 | 2020 |
| Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease O Bassegoda, P Olivas, L Turco, M Mandorfer, M Serra-Burriel, L Tellez, ... Clinical gastroenterology and hepatology 20 (10), 2276-2286. e6, 2022 | 56 | 2022 |
| Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease L Hartl, K Haslinger, M Angerer, G Semmler, M Schneeweiss‐Gleixner, ... Hepatology 76 (6), 1563-1575, 2022 | 55 | 2022 |
| Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease G Semmler, T Binter, K Kozbial, P Schwabl, S Hametner‐Schreil, ... Hepatology 73 (4), 1275-1289, 2021 | 55 | 2021 |
| Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease J Trebicka, W Gu, V de Ledinghen, C Aubé, A Krag, M Praktiknjo, ... Gut 71 (2), 402-414, 2022 | 54 | 2022 |
| Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension K Wöran, G Semmler, M Jachs, B Simbrunner, DJM Bauer, T Binter, ... Clinical Gastroenterology and Hepatology 20 (2), e251-e266, 2022 | 45 | 2022 |
| Safety of direct oral anticoagulants in patients with advanced liver disease G Semmler, K Pomej, DJM Bauer, L Balcar, B Simbrunner, T Binter, ... Liver International 41 (9), 2159-2170, 2021 | 42 | 2021 |
| Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension E Degasperi, MP Anolli, SCU Renteria, D Sambarino, M Borghi, ... Journal of hepatology 77 (6), 1525-1531, 2022 | 41 | 2022 |
| Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis G Semmler, K Wöran, B Scheiner, LW Unger, R Paternostro, J Stift, ... United European gastroenterology journal 8 (3), 321-331, 2020 | 38 | 2020 |
| Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease B Scheiner, L Steininger, G Semmler, LW Unger, P Schwabl, T Bucsics, ... Liver International 39 (1), 127-135, 2019 | 38 | 2019 |
| Non-invasive tests for clinically significant portal hypertension after HCV cure G Semmler, S Lens, EL Meyer, A Baiges, E Alvardo-Tapias, E Llop, ... Journal of hepatology 77 (6), 1573-1585, 2022 | 36 | 2022 |
| Metabolic dysfunction-associated fatty liver disease (MAFLD)—rather a bystander than a driver of mortality G Semmler, S Wernly, S Bachmayer, I Leitner, B Wernly, M Egger, ... The Journal of Clinical Endocrinology & Metabolism 106 (9), 2670-2677, 2021 | 36 | 2021 |
| Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD B Scheiner, L Balcar, RJ Nussbaumer, J Weinzierl, R Paternostro, ... Journal of hepatology 76 (5), 1090-1099, 2022 | 35 | 2022 |
| Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays G Semmler, MT Traugott, M Graninger, W Hoepler, T Seitz, H Kelani, ... Journal of clinical microbiology 59 (5), 10.1128/jcm. 02890-20, 2021 | 35 | 2021 |
| PIDDosome‐induced p53‐dependent ploidy restriction facilitates hepatocarcinogenesis VC Sladky, K Knapp, TG Szabo, VZ Braun, L Bongiovanni, H van den Bos, ... EMBO reports 21 (12), e50893, 2020 | 35 | 2020 |
